Cargando…

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment

In Huntington's disease (HD), the main clinical symptoms include depression, apathy, cognitive deficits, motor deficiencies and involuntary movements. Cognitive, mood and behavioral changes may precede motor symptoms by up to 15 years. The treatment of these diverse symptoms is challenging. Tet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molnar, Maria Judit, Molnar, Viktor, Fedor, Mariann, Csehi, Reka, Acsai, Karoly, Borsos, Beata, Grosz, Zoltan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866559/ https://www.ncbi.nlm.nih.gov/pubmed/35222108 http://dx.doi.org/10.3389/fpsyt.2021.825532

Ejemplares similares

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
por: Csehi, Réka, et al.
Publicado: (2022)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
por: Palacios-Garrán, Roberto, et al.
Publicado: (2022)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine
por: Molnar, Maria Judit, et al.
Publicado: (2020)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Editorial: Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists
por: Németh, György, et al.
Publicado: (2022)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Cariprazine Use in Early Psychosis: Three Case Reports
por: Coentre, Ricardo, et al.
Publicado: (2021)

Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up
por: Pappa, Sofia, et al.
Publicado: (2023)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System
por: Grunze, Heinz, et al.
Publicado: (2021)

Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review
por: Seeberg, Ida, et al.
Publicado: (2018)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence
por: Rancans, E., et al.
Publicado: (2023)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
por: Vrublevska, Jelena
Publicado: (2023)

Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series
por: Vannucchi, Tommaso, et al.
Publicado: (2022)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine
por: Moran, Robert A, et al.
Publicado: (2023)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder
por: Bogren, Mats, et al.
Publicado: (2022)

Editorial: Cognition in Mood Disorders
por: Oyesanya, Mayowa, et al.
Publicado: (2020)

Case report: Treatment-resistant schizophrenia with auto-aggressive compulsive behavior—Successful management with cariprazine
por: Renemane, Lubova, et al.
Publicado: (2023)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Social cognition and quality of life in Huntington's disease
por: Eddy, Clare M., et al.
Publicado: (2022)

Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report
por: Sahlsten Schölin, Johan, et al.
Publicado: (2023)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
por: Ivanov, Stanislav V., et al.
Publicado: (2022)

Prospective Assessment of Daily Patterns of Mood-Related Symptoms
por: Pilz, Luísa K., et al.
Publicado: (2018)

Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery
por: Taube, Maris
Publicado: (2021)

Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality
por: Marotta, Angela, et al.
Publicado: (2019)

Affective Computing for Late-Life Mood and Cognitive Disorders
por: Smith, Erin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hj4sdft54qjt75mvjj2ab1004o